Healthcare Sales & Marketing Network News: respiratory failure

Searching News Database: respiratory failure

HSMN NewsFeed - 19 Dec 2025
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 20 Aug 2025
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
Devices FDA

HSMN NewsFeed - 14 Apr 2025
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
Devices Personnel

HSMN NewsFeed - 7 Nov 2024
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Oct 2024
CHMP Maintains Negative Opinion on Translarna(TM) Reexamination
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Oct 2024
Inspira(TM) Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism
Devices

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Mar 2024
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA(R) (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Jun 2023
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
Biopharmaceuticals Regenerative Medicine Licensing

HSMN NewsFeed - 2 Nov 2022
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
Devices

HSMN NewsFeed - 1 Jun 2022
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries
Devices Distribution

HSMN NewsFeed - 2 May 2022
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany
Devices Group Purchasing

HSMN NewsFeed - 3 Feb 2022
Third Pole Therapeutics Closes $25M Financing - eNOfit(TM) Wearable Device Now Ready for Clinical Trials
Devices Venture Capital

HSMN NewsFeed - 20 Dec 2021
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb(R) in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
Devices

HSMN NewsFeed - 10 Sep 2021
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Devices Surgery FDA

HSMN NewsFeed - 13 Aug 2021
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Biopharmaceuticals

HSMN NewsFeed - 12 Aug 2021
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR(TM) Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
Devices FDA

HSMN NewsFeed - 6 Aug 2021
FDA Approves New Treatment for Pompe Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 13 May 2021
SpliSense Secures $28.5 Million in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 15 Apr 2021
Third Pole Therapeutics Secures $15 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.
Devices Venture Capital

HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Jan 2021
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
Devices Personnel

HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Dec 2020
PTC Announces Translarna(TM) Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Oct 2020
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)
Biopharmaceuticals Regenerative Medicine Licensing

HSMN NewsFeed - 21 Sep 2020
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners
Biopharmaceuticals

HSMN NewsFeed - 6 Aug 2020
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 31 Jul 2020
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
Devices

HSMN NewsFeed - 28 Jul 2020
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data
Devices

HSMN NewsFeed - 26 Jun 2020
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Jun 2020
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
Devices Product Launch

HSMN NewsFeed - 12 May 2020
CytoSorb(R) is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
Devices Regulatory

HSMN NewsFeed - 4 May 2020
CytoSorbents Promotes Vincent J. Capponi to President
Devices Personnel

HSMN NewsFeed - 29 Apr 2020
Medical Diagnostic Laboratories, L.L.C., Launches Serological Test for Coronavirus Disease 2019 (COVID-19) Antibodies in Human Serum
Diagnostics Product Launch

HSMN NewsFeed - 27 Apr 2020
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
Devices Personnel

HSMN NewsFeed - 13 Apr 2020
U.S. FDA Grants CytoSorb(R) Emergency Use Authorization for Use in Patients with COVID-19 Infection
Devices FDA

HSMN NewsFeed - 8 Apr 2020
Third Pole Therapeutics Announces Global Commercialization Agreement with Chiesi Group for Its Tankless, Portable Inhaled Nitric Oxide (iNO) Delivery System
Biopharmaceuticals Licensing

HSMN NewsFeed - 26 Mar 2020
FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL(R) DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 12 Mar 2020
Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies
Biopharmaceuticals

HSMN NewsFeed - 19 Feb 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Oct 2019
Third Pole Therapeutics Names Bill Athenson New CEO
Devices Drug Delivery Personnel

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 May 2019
Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax(R) (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates
Biopharmaceuticals

HSMN NewsFeed - 26 Mar 2019
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome
Biopharmaceuticals

HSMN NewsFeed - 19 Nov 2018
Philips Debuts Noninvasive Ventilator With High Flow Therapy to Improve Patient Care
Devices Regulatory Product Launch

HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Aug 2018
Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy
Biopharmaceuticals Regenerative Medicine FDA

HSMN NewsFeed - 5 Jun 2018
Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 Mar 2018
Respiratory Motion, Inc. is excited to announce FDA clearance for use of the ExSpiron(TM) 1Xi Minute Ventilation Monitor in Pediatric Patients
Devices FDA

HSMN NewsFeed - 21 Nov 2017
Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy
Biopharmaceuticals

HSMN NewsFeed - 15 Aug 2017
Philips announces agreement with Lakeland Health for advanced monitoring to improve patient safety
Devices Monitoring

HSMN NewsFeed - 11 Jul 2017
Prometic Announces Positive Long Term Clinical Data on Ryplazym(TM) in Plasminogen Congenital Deficiency and Provides Regulatory Update
Biopharmaceuticals

HSMN NewsFeed - 10 Jul 2017
Philips-sponsored Study Suggests Positive Airway Pressure Therapy Could Reduce COPD Patient Hospitalization
Devices

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jan 2017
Getinge Group Announces U.S. Launch of Total Lift Bed(TM) for ICU Patients
Devices Product Launch

HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Sep 2016
Validity of Mallinckrodt's INOMAX(R) Patent Claims Upheld
Biopharmaceuticals Devices Litigation

HSMN NewsFeed - 7 Sep 2016
FDA allows Phrixus’s IND for Carmeseal-MD(TM) (P-188 NF) in Duchenne muscular dystrophy (DMD)
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Jun 2016
Savara Pharmaceuticals Acquires Serendex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 1 Feb 2016
Proteostasis Therapeutics Receives FDA Fast Track Designation for PTI-428 in Patients With Cystic Fibrosis
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Oct 2015
Mallinckrodt's INOmax(R) Approved In Australia And Japan For Pulmonary Hypertension In Conjunction With Heart Surgery
Biopharmaceuticals Regulatory

HSMN NewsFeed - 6 Jul 2015
Strensiq(R) (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution

HSMN NewsFeed - 1 May 2015
Advanced Inhalation Therapies Granted European Orphan Drug Designation for Nitric Oxide for the Treatment of Cystic Fibrosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Aug 2014
Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Jul 2014
Akashi Therapeutics Receives Fast Track Designation for HT-100 from FDA for the Treatment of Duchenne Muscular Dystrophy
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Jul 2014
Akashi Therapeutics Receives Collective Funding of $1.5 Million to Support HT-100 Clinical Development
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 May 2014
Santhera Reports Positive Outcome for Catena(R)/Raxone(R) in Phase III DMD Trial Supported by Additional Respiratory Function Data
Biopharmaceuticals

HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Mar 2014
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN(R) In Very Young Children Born Small For Gestational Age
Biopharmaceuticals

HSMN NewsFeed - 31 Dec 2013
CytoSorbents Provides Clinical Update on CytoSorb Dosing Study
Devices

HSMN NewsFeed - 11 Sep 2013
ALung Technologies Raises $15.8 Million in Series B-1 Financing
Devices Venture Capital

HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 16 Jul 2013
Alexion’s Soliris(R) (eculizumab) Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica (NMO)
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 21 Jan 2013
Mallinckrodt Announces Approval of New Gablofen(R) Prefilled Syringe
Biopharmaceuticals Drug Delivery Neurology FDA

HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Apr 2012
Aerocrine AB Announces New US Leadership
Devices Personnel

HSMN NewsFeed - 6 Feb 2012
ALung Technologies Raises $10 Million in Series B Financing
Devices Venture Capital

HSMN NewsFeed - 3 May 2011
Thoratec Comments on Publication of HeartMate II(R) Bridge-to-Transplantation Post-Approval Study in JACC
Devices Cardiology

HSMN NewsFeed - 5 Jan 2011
FDA Extends Marketing Exclusivity for INOMAX(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Nov 2010
FDA Approves EGRIFTA(TM) (Tesamorelin for Injection): The First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-Infected Patients With Lipodystrophy
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Oct 2010
Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix Biliary Stents
Devices Interventional FDA

HSMN NewsFeed - 15 Jul 2010
Ikaria(R) Names Chief Science Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2010
Ikaria(R) Names New Head of Research & Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 May 2010
Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 17 May 2010
Teva Provides Update on Talampanel for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology

HSMN NewsFeed - 10 Mar 2010
Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jan 2010
Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
Devices Cardiology FDA

HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Oct 2009
Covidien Announces Global Launch of Mallinckrodt TaperGuard Line of Endotracheal Tubes
Devices

HSMN NewsFeed - 16 Oct 2009
FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Jun 2009
Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin(R) (Human Growth Hormone)
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Feb 2009
Teleflex Medical and ResMed Corporation Sign NIV Mask Distribution Agreement
Devices Distribution

HSMN NewsFeed - 6 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 22 Sep 2008
Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Sep 2008
Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
Devices Monitoring

HSMN NewsFeed - 2 Sep 2008
Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 25 Aug 2008
Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jul 2008
Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jul 2008
Ikaria(R) Strengthens Research & Development Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Apr 2008
Atom Medical Adopts Masimo Rainbow SET Technology
Devices Monitoring

HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Mar 2008
Daxor Announces Publication of Clinical Study Demonstrating Blood Volume Analysis Benefits Critically Ill Surgical Patients
Devices

HSMN NewsFeed - 13 Mar 2008
Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology

HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Feb 2008
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
Biopharmaceuticals Licensing

HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Jan 2008
Angiotech and Symphony Medical Announce Licensing Agreement
Devices Cardiology Licensing

HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 13 Dec 2007
Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Biopharmaceuticals

HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Dec 2007
Medtronic Files PMA Application for FDA Approval of Talent(TM) Abdominal Stent Graft System
Devices Interventional FDA

HSMN NewsFeed - 8 Nov 2007
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Biopharmaceuticals Licensing

HSMN NewsFeed - 8 Nov 2007
Shire Expands its Human Genetic Therapies Pipeline Through In-Licensing Agreement With Amicus Therapeutics
Biopharmaceuticals Licensing

HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 10 Oct 2007
Multicenter PolyHeme Trauma Study Presented at the American College of Surgeons 93rd Annual Clinical Congress
Biopharmaceuticals

HSMN NewsFeed - 21 Sep 2007
Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Sep 2007
The Society of Thoracic Surgeons Adds Cerebral Oximetry as Metric to STS Adult Cardiac Surgery Database
Devices Monitoring Surgery

HSMN NewsFeed - 1 Aug 2007
Masimo Announces FDA Clearance for Additional Neonatal Parameters for Rainbow SET, Including Continuous and Noninvasive Measurement of Methemoglobin
Devices Monitoring FDA

HSMN NewsFeed - 14 Jun 2007
Critical Biologics Appoints Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jun 2007
OmniGuide Announces Start of Clinical Trial Comparing the BeamPath Flexible CO2 Laser Fiber to the Pulse Dye Laser
Devices

HSMN NewsFeed - 1 Jun 2007
FDA Approves Norditropin(R)for Treatment of Short Stature Associated with a Rare Genetic Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Mar 2007
GTC Biotherapeutics Grants Expanded License to PharmAthene for Further Development of Protexia(R)
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Feb 2007
sanofi-aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Dec 2006
Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
Biopharmaceuticals

HSMN NewsFeed - 14 Nov 2006
New Data on Otsuka's Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting
Biopharmaceuticals Cardiology

HSMN NewsFeed - 30 Oct 2006
Valeant Pharmaceuticals Presents End-of-Treatment Results of DIRECT Trial for Infergen at the American Association for the Study of Liver Diseases 2006 Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 6 Sep 2006
OVATION and Cardinal Health Announce FDA Approval Letter for Manufacturing of Biologic Therapy To Treat Rare Genetic Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Jun 2006
sanofi-aventis Announces Update to Ketek(R) (Telithromycin) U.S. Prescribing Information
Biopharmaceuticals FDA

Return to NewsFeed

Additional items found! 36

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 36 additional stories matching:
respiratory failure
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.